-+ 0.00%
-+ 0.00%
-+ 0.00%

PainReform Commences Development Plan For OcuRing-K, LayerBio's Patented, Drop-Less, Intraoperatively Administered Sustained-Release Ocular Therapy

Benzinga·12/02/2025 14:20:33
Listen to the news

PainReform Ltd. (NASDAQ:PRFXtoday announced, through its pharmaceutical division, the commencement of its development plan for OcuRing™-K, LayerBio's patented, drop-less, intraoperatively administered sustained-release ocular therapy designed to deliver controlled, site-specific release of ketorolac following cataract surgery. Following the closing of PainReform's majority investment in LayerBio and the integration of OcuRing-K into PainReform's development portfolio, the Company conducted a methodical internal assessment with LayerBio's management team to define development priorities and establish a clear path for advancing the program. Work is now progressing toward the Phase II clinical trial.